207eP A real-world study on efficacy of different second-line treatment strategies following the progression of first-line immunotherapy and its combination therapies in driver gene-negative advanced non-small cell lung cancer

Key Points

• This study aims to evaluate second-line treatment strategies for patients with driver-negative advanced non-small cell lung cancer after progression on first-line immunotherapy.
• Conducted as a dual-center study
• Included patients with driver-negative advanced NSCLC
• Evaluated various second-line treatments
• Analyzed real-world treatment outcomes
• Identified varying efficacy of second-line treatments
• Noted early resistance in patients after first-line therapy
• Provided insights on optimal treatment strategies for improved outcomes